Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 15, 2025OncogeneOpen Access

METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis

View Full Paper
Ask AI
Bookmark
Share

Authors

GBGuglielmo BoveMBMehrad BabaeiABAlberto Bueno-Costa

Discussion

Loading...

Member takes

Overview

This study demonstrates METTL16 regulates MXD4 in AML, suggesting potential therapeutic pathways targeting MYC.

Key Points

  • Inhibition of METTL16 decreases MXD4 levels, promoting MYC activity essential for leukemia growth.
  • Overexpression of METTL16 in primary AML cells was linked to increased leukemia cell proliferation.
  • Targeting METTL16 offers a novel approach to restore MXD4 levels and inhibit MYC-driven leukemogenesis.
  • Findings establish a METTL16-MXD4 oncogenic axis that may provide new cancer treatment strategies.

Cite This Study

Bove et al. (2025) studied this question.

synapsesocial.com/papers/68d4204e713b0b5dfea68d44https://doi.org/10.1038/s41388-025-03563-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia2025
  2. 2Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia2025 · 1 citations
  3. 3The role of METTL14 in the progression of chronic myeloid leukemia2025 · 4 citations
  4. 4The m6A methyltransferase METTL14 promotes oncogenic Kras induced juvenile myelomonocytic leukemia through dysregulating autophagy2025
  5. 5HOXA9/METTL3/BMI1 axis is required for promoting anthracycline resistance in acute myeloid leukemia cells by modulating BMI1 expression through  mRNA m6A modification2025